Bruker Corporation BRKR has witnessed strong momentum over the past year. Shares of the company have risen 66.3% compared with the industry’s 66.4% growth. The S&P 500 composite has increased 18.2% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
BRKR designs and manufactures proprietary life science and materials research systems and associated products. The company serves multiple customers in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology and in-vitro diagnostics. The company reports through four segments — Bruker Scientific Instruments (BSI) Biosystems, BSI Microbiology and Infection Diagnostics (BMID), BSI NANO, and Bruker Energy & Supercon Technologies (BEST).
Factors Favoring BRKR’s Share Price Growth
Bruker’s share price is trending upward, prompted by the strong demand across biopharma, security detection, molecular diagnostics and mass spectrometry. In the first half of 2026, its former CALID businesses’ revenues were $626.6 million, up from $565.9 million a year earlier and higher by a mid-single-digit percentage at constant exchange rates. Growth was driven by mass spectrometry, including the Tofwerk acquisition, with additional gains in biopharma, security detection and European academic and government markets. Molecular diagnostics also grew, although microbiology was roughly flat.
Additionally, Bruker’s preclinical imaging portfolio serves cancer research, neuroimaging, orthopedics, cardiac imaging and stroke models, with higher-field systems supporting applications that require greater resolution. The first quarter of 2026 included acceptance of an 18 Tesla preclinical MRI system, while first-half 2026 NMR preclinical and preclinical imaging orders both rose at double-digit rates year over year. These order trends show continued customer investment despite broader academic funding weakness.
From a solvency viewpoint, Bruker exited the second quarter of 2026 with cash and cash equivalents of $184.9 million compared with $298.8 million at the end of 2025. Meanwhile, the current portion of long-term debt and finance lease obligations was only $10.1 million, well below the company’s cash balance. Bruker also had total current assets of $2.23 billion compared with current liabilities of $1.20 billion as of June 30, 2026, supporting its near-term solvency position. Overall, limited near-term debt maturities and adequate current asset coverage provide financial flexibility.
Image Source: Zacks Investment Research
Factors That May Offset BRKR’s Gains
Bruker is reorganizing its scientific instruments businesses while addressing underperforming assets. Second-quarter 2026 GAAP results included a $134.9 million noncash goodwill impairment tied to automation and spatial biology businesses that continued to generate operating losses. The new BSI Biosystems restructuring plan is expected to cost $12-$15 million and be completed during 2026. The reorganization also triggered another interim goodwill impairment review for the third quarter. These actions may improve portfolio focus, but they add execution demands as Bruker integrates operations.
Also, Bruker’s global revenue base keeps reported growth and earnings sensitive to exchange-rate changes. The company reduced its full-year 2026 expected currency revenue benefit to about 0.5% from 1.5%. It now assumes an approximately $0.10, or 5%, currency drag on non-GAAP EPS. The revised currency outlook lowered expected full-year revenues to $3.54-$3.57 billion while EPS guidance remained $2.10-$2.15, showing that rate movements can alter reported growth even when underlying demand assumptions are unchanged.
A Look at BRKR’s Estimates
The Zacks Consensus Estimate for 2026 EPS has remained unchanged at $2.12 in the past 30 days.
The company has an estimated long-term EPS growth rate of 15.4%, in line with the industry’s growth rate.
Stocks to Consider
Some better-ranked stocks in the broader medical space are Veracyte VCYT, OPKO Health OPK and Teleflex TFX.
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPKO Health, sporting a Zacks Rank of 1 at present, has an estimated 2026 earnings growth rate of 23.3% compared with the industry’s 16.6% growth. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 95.1%. OPK shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Teleflex, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bruker Corporation (BRKR): Free Stock Analysis Report
Teleflex Incorporated (TFX): Free Stock Analysis Report
OPKO Health, Inc. (OPK): Free Stock Analysis Report
Veracyte, Inc. (VCYT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).